Synovial sarcomas (SySa) account for 5-10% of all soft tissue sarcomas. In the majority, SySa arise mainly in adolescents and young adults with predominance in male gender. They are molecularly characterized by a reciprocal t(X;18) translocation which juxtaposes the SS18 gene on chromosome 18 to either the SSX1, the SSX2, or rarely to the SSX4 gene on the X chromosome. The SS18-SSX chimeric proteins act as transcriptional co-activators, leading to deregulation of oncogenic pathways. Current treatment protocols for synovial sarcoma are based on radical surgery and standardized chemo- and radiotherapy; however, prognosis is still poor in advanced disease. Targeted therapeutic approaches, which have significantly improved the clinical course of patients with e.g. GIST or dermato- fibrosarcoma protuberans, are still lacking for SySa. Several receptor tyrosine kinases have been shown to be expressed in SySa, including the EGF receptor, and the IGF-IR, leading to an activation of the PI3K/AKT signaling pathway. Beyond kinase signals, we have shown an essential role of WNT/ß-catenin signals in SySa.

Our current studies analyze the functional relevance of diverse oncogenic signaling pathways in synovial sarcoma, aiming at a better understanding of tumor biology as a basis for the definition of innovative therapeutic approaches.

Accounting for ~5-10% of all soft tissue sarcomas, myxoid liposarcoma (MLS) represent ~20% of all malignant adipocytic tumors. In the majority of cases, MLS arise in younger adults, defining the most frequent LS subtype in patients <20 years of age. Clinically, MLS are characterized by a high rate of local recurrences and development of metastases affecting in total ~40% of patients. Morphologically, MLS comprise a large spectrum ranging from paucicellular myxoid tumors to hypercellular round cell sarcomas associated with a more aggressive clinical course. Genetically, the vast majority of MLS is characterized by a chromosomal t(12;16)(q13;p11) translocation, juxtaposing the FUS and DDIT3 genes. About 5% of all MLS display an alternative chromosomal t(12;22) rearrangement leading to an EWSR1-DDIT3 gene fusion. The resulting FUS‑DDIT3 and EWSR1-DDIT3 fusion proteins are thought to play an essential role in MLS pathogenesis, acting as transcriptional (dys-)regulators; however, the functional details and the specific impact of the chimeric fusion protein on oncogenic signaling pathways known to be activated in MLS is incompletely understood. It has been shown recently that MLS are characterized by EGFR, PDGFRB, RET, and MET as well as VEGFR1 activation sustained by autocrine/paracrine loops and receptor tyrosine kinase (RTK) cross-talk, resulting in activation of the downstream PI3K/AKT signaling pathway. PI3K/AKT signaling is a central hub in the transduction of different RTK inputs involving diverse growth-controlling effectors such as GSK-3ß and the cell cycle regulator Cyclin D1. Current therapeutic approaches in high-grade MLS complement radical surgery with radiotherapy and/or conventional chemotherapy based on anthracyclines and ifosfamide. However, though MLS display higher chemosensitivity than other LS, the high rate of recurrences and metastases in MLS underlines the urgent need of novel therapeutic options.

Our current studies analyze the functional relevance of diverse oncogenic signaling pathways in myxoid liposarcoma, aiming at a better understanding of tumor biology as a basis for the definition of innovative therapeutic approaches.